Cat.#: ASSD-141
| Description | MTT is a tetrazolium dye that is frequently employed in experiments to measure the rate of cell proliferation or growth. When MTT is introduced into living cells, it undergoes a chemical transformation facilitated by certain enzymes called NAD(P)H-dependent cellular oxidoreductases, leading to the production of formazan which is a bluish or purplish insoluble substance. |
| Synonyms | Thiazolyl blue tetrazolium bromide |
| Size | 500 mg, 1 g |
| Applications | For used quantitation of cell viability and cell proliferation where the color intensity can be measured colormetrically (at 540 or 570 nM). |
| Chemical Name | 3-(4,5-dimethyl-1,3-thiazol-2-yl)-2,5-diphenyl-2H-tetrazol-3-ium bromide |
| Molecule Weight | 414.32 |
| Molecular formula | C18H16N5SBr |
| CAS Number | 298-93-1 |
| PubChem identifier | 64965 |
| MDL Number | MFCD00011964 |
| Purity | >97% |
| Solubility | Soluble in water (5 mg/ml) |
| Storage | Store at -20° C |
| Shipping | Shipped at 4°C |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-169 | Calcium Ionophore A23187 (AC169) | 1mg, 5mg, 10 mg | inquiry |
| ASSD-182 | 9-(2-Carboxy-2-cyanovinyl)julolidine (AC182) | 5 mg | inquiry |
| ASSD-178 | 5-(Iodoacetamido)fluorescein (AC178) | 25 mg, 100 mg, 250 mg | inquiry |
| ASSD-124 | Fluorescent β2 antagonist [(S)-propranolol-green] (AC124) | 500 μg | inquiry |
| ASSD-153 | Brilliant Blue G (AC153) | 1g | inquiry |
| ASSD-223 | Antifade Fluorescence Mounting Medium (aqueous) (AC223) | 10 mL | inquiry |
| ASSD-199 | 4,7-Dioxaoctylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[2-fluoro-4′-phosphophenylacetic Acid] Diamide (AC199) | 500 μg | inquiry |
| ASSD-152 | Biocytin (AC152) | 10 mg, 50 mg | inquiry |
| ASSD-219 | Tetramethylrhodamine-6-maleimide (AC219) | 5 mg | inquiry |
| ASSD-127 | Fluorescent H3 antagonist [clobenpropit] (AC127) | 50 μg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.